Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
Atrophy
cortical lesions
dimethyl fumarate
gray matter
multiple sclerosis
treatment response
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
30
6
2022
medline:
19
10
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
Data on the effect of dimethyl fumarate (DMF) on focal and diffuse gray matter (GM) damage, a relevant pathological substrate of multiple sclerosis (MS)-related disability are lacking. To evaluate the DMF effect on cortical lesions (CLs) accumulation and global and regional GM atrophy in subjects with relapsing-remitting MS. A total of 148 patients (mean age 38.1 ± 9.7 years) treated with DMF ended a 2-year longitudinal study. All underwent regular Expanded Disability Status Scale (EDSS assessment), and at least two 3T-magnetic resonance imaging (MRI) at 3 and 24 months after DMF initiation. CLs and changes in global and regional atrophy of several brain regions were compared with 47 untreated age and sex-matched patients. DMF-treated patients showed lower CLs accumulation (median 0[0-3] vs 2[0-7], Beyond the well-known effect on disease activity, these results provide evidence of the effect of DMF through reduced progression of focal and diffuse GM damage.
Sections du résumé
BACKGROUND
Data on the effect of dimethyl fumarate (DMF) on focal and diffuse gray matter (GM) damage, a relevant pathological substrate of multiple sclerosis (MS)-related disability are lacking.
OBJECTIVE
To evaluate the DMF effect on cortical lesions (CLs) accumulation and global and regional GM atrophy in subjects with relapsing-remitting MS.
METHODS
A total of 148 patients (mean age 38.1 ± 9.7 years) treated with DMF ended a 2-year longitudinal study. All underwent regular Expanded Disability Status Scale (EDSS assessment), and at least two 3T-magnetic resonance imaging (MRI) at 3 and 24 months after DMF initiation. CLs and changes in global and regional atrophy of several brain regions were compared with 47 untreated age and sex-matched patients.
RESULTS
DMF-treated patients showed lower CLs accumulation (median 0[0-3] vs 2[0-7],
CONCLUSIONS
Beyond the well-known effect on disease activity, these results provide evidence of the effect of DMF through reduced progression of focal and diffuse GM damage.
Identifiants
pubmed: 35765211
doi: 10.1177/13524585221104014
doi:
Substances chimiques
Dimethyl Fumarate
FO2303MNI2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM